FOLH1 and prostate carcinoma: For instance, current guidelines for using 177Lu-PSMA-617 in prostate cancer recommend molecular imaging to evaluate tumor PSMA expression (68Ga/18F-PSMA PET or 99mTc-PSMA SPECT/scintigraphy) 16.